Lyndal Hesterberg - OncoCyte Corp Chief Scientific Officer
| OCX Stock | USD 2.44 0.09 3.56% |
Insider
Lyndal Hesterberg is Chief Scientific Officer of OncoCyte Corp since 2019.
| Tenure | 5 years |
| Address | 15 Cushing, Irvine, CA, United States, 92618 |
| Phone | 949 409 7600 |
| Web | https://www.oncocyte.com |
OncoCyte Corp Management Efficiency
The company has Return on Asset of (0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.59 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, OncoCyte Corp's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.7 M in 2024, whereas Total Assets are likely to drop slightly above 49.1 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexander Dimitrief | Sotera Health Co | 65 | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
| Jill Mullan | iSpecimen | 59 | |
| John Boniface | Sera Prognostics | 62 | |
| Andrew Macan | Neuronetics | 51 | |
| Carol Tillis | Personalis | N/A | |
| Sally Turner | Sotera Health Co | N/A | |
| Yusheng Han | Burning Rock Biotech | 45 | |
| DPHIL FRCP | Personalis | 50 | |
| Shaokun Chuai | Burning Rock Biotech | 45 | |
| David MD | iSpecimen | N/A | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| Paul Kearney | Sera Prognostics | 56 | |
| Keith Meadors | Precipio | N/A | |
| BBus CA | Intelligent Bio Solutions | 60 | |
| Debra Zack | Exagen Inc | 65 | |
| Stephen MS | Neuronetics | 60 | |
| Alex Arzeno | Intelligent Bio Solutions | N/A | |
| Atul Butte | Personalis | N/A | |
| MingChou Lee | Exagen Inc | N/A | |
| Gary Pestano | Biodesix | 57 | |
Management Performance
| Return On Equity | -1.65 | ||||
| Return On Asset | -0.19 |
OncoCyte Corp Leadership Team
Elected by the shareholders, the OncoCyte Corp's board of directors comprises two types of representatives: OncoCyte Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoCyte. The board's role is to monitor OncoCyte Corp's management team and ensure that shareholders' interests are well served. OncoCyte Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoCyte Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Liu, Controller, Director | ||
| Andrea James, Chief Officer | ||
| Michael West, Director, CEO of Biotime Inc and President of Biotime Inc | ||
| Ekkehard MD, Chief Officer | ||
| Joshua Riggs, Interim Officer | ||
| Tony Kalajian, Senior Vice President Chief Accounting Officer | ||
| Andrew Last, Independent Director | ||
| YuhMin Chiang, Senior Development | ||
| Douglas Ross, Chief Medical Officer | ||
| Melinda Griffith, Independent Director | ||
| Anish John, Chief Officer | ||
| William Annett, Advisor | ||
| Peter Hong, General VP | ||
| Andrew Arno, Independent Director | ||
| Gisela Paulsen, COO Pres | ||
| Sara Riordan, Director Education | ||
| Albert Parker, Chief Operating Officer | ||
| Lyndal Hesterberg, Chief Scientific Officer | ||
| Ronald Andrews, President, Chief Executive Officer, Director | ||
| Cavan Redmond, Independent Chairman of the Board | ||
| Padma Sundar, Senior Vice President - Marketing and Market Access | ||
| Mitchell Levine, Chief Financial Officer | ||
| Robert Seitz, Head Oncology | ||
| Sandra ODonald, Senior Operations |
OncoCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoCyte Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.65 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (55.43) % | ||||
| Current Valuation | 43.22 M | ||||
| Shares Outstanding | 16.84 M | ||||
| Shares Owned By Insiders | 15.95 % | ||||
| Shares Owned By Institutions | 50.58 % | ||||
| Number Of Shares Shorted | 194.19 K | ||||
| Price To Earning | (12.20) X | ||||
| Price To Book | 4.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.